UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000016598
Receipt number R000019263
Scientific Title Study of visual and anatomical outcomes of second year aflibercept in good visual acuity baseline of wet age-related macular degeneration
Date of disclosure of the study information 2015/02/22
Last modified on 2023/06/06 09:45:17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of visual and anatomical outcomes of second year aflibercept in good visual acuity baseline of wet age-related macular degeneration

Acronym

Study of second year aflibercept in patients with wAMD

Scientific Title

Study of visual and anatomical outcomes of second year aflibercept in good visual acuity baseline of wet age-related macular degeneration

Scientific Title:Acronym

Study of second year aflibercept in patients with wAMD

Region

Japan


Condition

Condition

Age-related macular degeneration

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the efficacy of second year aflibercept with monthly treat and extend regimen in patients with good visual acuity wAMD.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change of best-collected visual acuity and proportion of improved, maintained and deteriorated visual acuity at month 24 from 12 after initial injection of aflibercept

Key secondary outcomes

Change of (best-collected visual acuity) BCVA, central macular thickness, subretinal fluid and polyps regression


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Eylea (aflibercept)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) baseline BCVA in the study eye over 0.5 (Decimal VA)
2) AMD with Subfoveal fluid on fluorescent angiography, indocyanine green angiography and/or optical coherence tomography
3) Willingness to provide written informed consent
4) outpatient
5) second year aflibercept treatment

Key exclusion criteria

1) Greatest Linear Dimension (GLD) of the total lesion area <12 Macular Photocoagulation Study Disc Areas
2) Presence of subretinal hemorrhage, scar or macular fibrosis (>50% lesion area)
3) Prior treatment with anti-VEGF drug, photodynamic therapy
4) Prior treatment with dexamethasone (<6 months) or triamcinolone (<30 days), intraocular surgery (<3 months)
5) Active intraocular inflammation
6) Hypersensitivity or allergy to fluorescein or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products
7) Patient who the doctor in charge judges are ineligible for the study

Target sample size

42


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hidenori Takahashi

Organization

Jichi Medical University

Division name

Department of Ophthalmology

Zip code


Address

3311-1 Yakushiji, Shimotsuke-shi, Tochigi-ken, Japan 329-0498

TEL

0285-58-7382

Email

takahah-tky@umin.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hidenori Takahashi

Organization

Jichi Medical University

Division name

Department of Ophthalmology

Zip code


Address

3311-1 Yakushiji, Shimotsuke-shi, Tochigi-ken, Japan 329-0498

TEL

0285-58-7382

Homepage URL


Email

takahah-tky@umin.ac.jp


Sponsor or person

Institute

Department of Ophthalmology, Jichi Medical University

Institute

Department

Personal name



Funding Source

Organization

Bayer Yakuhin Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

JCHO Tokyo Shinjuku Medical Center

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 02 Month 22 Day


Related information

URL releasing protocol

https://doi.org/10.2147/OPTH.S160961

Publication of results

Published


Result

URL related to results and publications

https://doi.org/10.2147/OPTH.S160961

Number of participants that the trial has enrolled

39

Results

Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study.
Shinichi Sakamoto, Hidenori Takahashi, Yuji Inoue, Yusuke Arai, Satoru Inoda, Natsuko Kakinuma, Yujiro Fujino, Tatsuro Tanabe, Hidetoshi Kawashima, Yasuo Yanagi
Clinical ophthalmology (Auckland, N.Z.) 12 1137-1147 2018

Results date posted

2023 Year 06 Month 06 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

 Japanese Age-related Macular Degeneration

Participant flow

Recruited at each facility for 2 years of regular medical care

Adverse events

None

Outcome measures

Visual Acuity and Central Subfield Thickness

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 01 Month 08 Day

Date of IRB

2015 Year 02 Month 16 Day

Anticipated trial start date

2015 Year 02 Month 22 Day

Last follow-up date

2016 Year 08 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2017 Year 08 Month 31 Day


Other

Other related information



Management information

Registered date

2015 Year 02 Month 22 Day

Last modified on

2023 Year 06 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019263


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name